Kikura-Hanajiri Ruri, Kawamura Nahoko Uchiyama Maiko, Goda Yukihiro
National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya, Tokyo, 158-8501, Japan.
Drug Test Anal. 2014 Jul-Aug;6(7-8):832-9. doi: 10.1002/dta.1584. Epub 2013 Dec 26.
To counter the spread of the many analogues of psychoactive substances, the Pharmaceutical Affairs Law in Japan was amended in 2006 to establish a new category - Designated Substances - in order to more promptly control these drugs. As of March 2013, 106 substances (including one plant, Salvia divinorum) were listed in the category of Designated Substances, and 13 of them had had their category changed from Designated Substances into the much stricter category, Narcotics. However, new analogues of controlled substances, especially synthetic cannabinoids, appeared one-by-one since the new category was introduced. To avoid a cat-and-mouse game between regulators and illicit drug manufacturers, a comprehensive system (generic scheduling) for designating naphthoylindole-type synthetic cannabinoids, with particular substituents, was introduced into the Designated Substances in 2013. Since late 2012, the naphthoylindole-type compounds have been gradually replaced by other types of synthetic cannabinoids, such as cyclopropylmethanones, cannabimimetic carboxamide derivatives, adamanthoyl indoles, and cannabimimetic quinolinyl carboxylates. After the enforcement of the generic scheduling for designating naphthoylindoles in March 2013, these naphthoylindoles have been completely replaced by other types and have rarely been detected in the products. New types of psychoactive substances, including opioid receptor agonists (e.g. AH-7921, MT-45), hallucinogenic phenethylamines (e.g. NBOMe-type compounds), and thiophene derivatives (e.g. methiopropamine, α-PVT) have also appeared. The almost infinite possibilities of altered structures of chemicals make it difficult to carry out effective and exhaustive scheduling. To prevent the widespread distribution and abuse of these new psychoactive substances, continuous and dedicated monitoring for the emergence of these substances is necessary.
为应对多种精神活性物质类似物的传播,日本《药事法》于2006年修订,设立了一个新类别——指定物质,以便更迅速地管控这些药物。截至2013年3月,有106种物质(包括一种植物,即鼠尾草属植物)被列入指定物质类别,其中13种物质的类别已从指定物质变更为更为严格的麻醉药品类别。然而,自引入新类别以来,受管制物质的新类似物,尤其是合成大麻素,不断出现。为避免监管机构与非法药品制造商之间的猫捉老鼠游戏,2013年在指定物质中引入了一种全面的系统(通用列管),用于指定具有特定取代基的萘甲酰基吲哚型合成大麻素。自2012年末以来,萘甲酰基吲哚型化合物已逐渐被其他类型的合成大麻素取代,如环丙基甲酮、大麻素模拟羧酰胺衍生物、金刚烷甲酰基吲哚和大麻素模拟喹啉基羧酸盐。2013年3月对萘甲酰基吲哚进行通用列管后,这些萘甲酰基吲哚已完全被其他类型取代,在产品中很少被检测到。新型精神活性物质,包括阿片受体激动剂(如AH - 7921、MT - 45)、致幻苯乙胺(如NBOMe型化合物)和噻吩衍生物(如甲硫丙胺、α - PVT)也已出现。化学物质结构改变的可能性几乎无穷无尽,这使得实施有效且详尽的列管变得困难。为防止这些新型精神活性物质的广泛流通和滥用,有必要持续且专门地监测这些物质的出现情况。